Correspondence 0001493152-23-000150 from AIxCrypto Holdings, Inc. (AIXC)

AIxCrypto Holdings, Inc.
Date: Jan. 3, 2023 · CIK: 0001460702 · Accession: 0001493152-23-000150

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

January 5, 2023

Author

Not clearly detected

Form

CORRESP

Company

AIxCrypto Holdings, Inc.

Letter

Re: Qualigen Therapeutics, Inc. – Request for Acceleration

January 3, 2023

VIA EDGAR

United States Securities and Exchange Commission

F Street, NE

Washington, D.C. 20549

Attention: Joshua Gorsky

Registration Statement on Form S-3

File No. 333- 269088

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Qualigen Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 269088) (the “Registration Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on Thursday, January 5, 2023, or as soon thereafter as practicable.

The Registrant hereby authorizes Wendy Grasso, Esq. of Reed Smith LLP, attorney for the Registrant, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso, Esq. at (212) 549-0216.

QUALIGEN THERAPEUTICS, INC.

By: /s/ Michael Poirier

Michael Poirier

Chairman & Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

January
3, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, NE

Washington,
D.C. 20549

Attention:
Joshua Gorsky

    Re:
    Qualigen Therapeutics, Inc. – Request for Acceleration

    Registration Statement on Form S-3

    File No. 333- 269088

Ladies
and Gentlemen:

Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Qualigen Therapeutics, Inc. (the “Registrant”) hereby
requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 269088) (the “Registration
Statement”), so that it may become effective at 4:30 p.m. Eastern Standard Time on Thursday, January 5, 2023, or as soon
thereafter as practicable.

The
Registrant hereby authorizes Wendy Grasso, Esq. of Reed Smith LLP, attorney for the Registrant, to orally modify or withdraw this request
for acceleration.

The
Registrant requests that it be notified of such effectiveness by a telephone call to Wendy Grasso, Esq. at (212) 549-0216.

    QUALIGEN THERAPEUTICS, INC.

    By:
     /s/ Michael Poirier

    Michael Poirier

    Chairman & Chief Executive Officer

SecProbe.io